Personalised Dose Optimisation of Zestril Supported by the Digital Blood Pressure Diary in a Primary Care Environment in England: Pragmatic Observational Pilot Study for Remote Hypertension Treatment

Inclusion criteria

• Adults aged 18 years and older.
• Patients diagnosed with uncomplicated essential (primary) hypertension eligible for Zestril per SmPC for hypertension management.
• Participants must provide written informed consent to participate in the study, including agreeing to adhere to the study procedures.
• Have access to and be able to use a suitable smartphone independently, running either iOS version 15 or later or Android version 10 or later.

Exclusion criteria

• Clinically significant abnormal blood results as judged by the investigator (exclude patients with known renal impairment).
• History of clinically important medical conditions that would compromise a patient's ability to participate safely (including an allergic reaction to Zestril/lisinopril or any other medicine and/or other contraindications and interactions listed in Zestril's SmPC).
• Patients with a strongly activated renin-angiotensin-aldosterone system (in particular, renovascular hypertension, salt and /or volume depletion, cardiac decompensation, or severe hypertension) as per SmPC
• Participants who are unwilling or unable to participate in remote study procedures, including home BP monitoring, remote consultations, and data submission as judged by the investigator.
• Any condition associated with poor compliance including alcoholism or drug dependence.
• Participants with cognitive impairments or language barriers that hinder their ability to understand and comply with study instructions and e-questionnaires.
• Failure to satisfy the investigator of fitness to participate for any other reason.